About Edesa Biotech
Edesa Biotech is a company based in Toronto (Canada) founded in 2015 by Par Nijhawan. The company has 16 employees as of September 30, 2024. Edesa Biotech offers products and services including Monoclonal Antibodies and Host Directed Therapeutics. Edesa Biotech operates in a competitive market with competitors including LEO Pharma, Incyte, Nimbus Therapeutics, Escient Pharmaceuticals and Aclaris Therapeutics, among others.
- Headquarter Toronto, Canada
- Employees 16 as on 30 Sep, 2024
- Founders Par Nijhawan
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Edesa Biotech, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$7.19 M (USD)-16.46as on Sep 30, 2025
-
EBITDA
-$7.79 M (USD)-14.11as on Sep 30, 2025
-
Latest Funding Round
$3.5 M (USD), Post-IPO
Jun 16, 2026
-
Investors
PharmaScience
& 8 more
-
Employee Count
16
as on Sep 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Edesa Biotech
Edesa Biotech is a publicly listed company on the NASDAQ with ticker symbol EDSA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Edesa Biotech
Edesa Biotech offers a comprehensive portfolio of products and services, including Monoclonal Antibodies and Host Directed Therapeutics.
Antibodies targeting immune dysregulation in inflammatory diseases
Treatments modulating pathways for multiple immune-related conditions
People of Edesa Biotech
Unlock access to complete
Funding Insights of Edesa Biotech
Investors in Edesa Biotech
Edesa Biotech has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include PharmaScience, Canadian Space Agency and Velan Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investment opportunities in healthcare are managed by Broadfin Capital.
|
Locked | Locked | Locked | |
|
Lumira Ventures is engaged in life sciences venture capital investment.
|
Locked | Locked | Locked |
Investor details for Edesa Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Edesa Biotech
Investment portfolio details for Edesa Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Edesa Biotech
Detailed financials for Edesa Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Edesa Biotech Comparisons
Peer comparison for Edesa Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Edesa Biotech
Edesa Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as LEO Pharma, Incyte, Nimbus Therapeutics, Escient Pharmaceuticals and Aclaris Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drugs for treating dermatology diseases
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
Detailed competitors of Edesa Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Edesa Biotech
Complete news archive for Edesa Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Edesa Biotech
Edesa Biotech was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Edesa Biotech is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Par Nijhawan is the current CEO of Edesa Biotech. They have also founded this company.
As of Sep 30, 2024, the latest employee count at Edesa Biotech is 16.
Edesa Biotech was founded in 2015 and is based in Toronto, Canada. Focus is placed on the biotechnology sector, where topical therapeutics for dermatological and gastrointestinal conditions are developed. Specific targets include contact dermatitis, hemorrhoids, and anal fissures. The lead product, EB-01, is advanced to Phase II trials for allergic contact dermatitis. Phase I candidates consist of EB-05 for irritant contact dermatitis, EB-02 for hemorrhoids, and EB-04 for anal fissures.
Edesa Biotech's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and LEO Pharma.
Edesa Biotech offers Monoclonal Antibodies and Host Directed Therapeutics.
Yes, Edesa Biotech is publicly traded on NASDAQ under the ticker symbol EDSA.
Edesa Biotech has 9 investors. Key investors include PharmaScience, Canadian Space Agency, Velan Capital, Nantahala Capital Management, and Rubric Capital.
The ticker symbol of Edesa Biotech is EDSA on NASDAQ.